NSCI Netscientific Plc

TIDMNSCI

RNS Number : 4155J

NetScientific PLC

21 December 2020

NetScientific plc

("NetScientific" or the "Company")

PDS Biotech Announces Mount Sinai Publication of Studies Showing Superior Induction of Antibodies by Versamune â -based COVID-19 Vaccine

Versamune â T-cell activating platform demonstrates breadth of

anti-SARS-CoV-2 immune responses in a COVID-19 vaccine

London, UK - 21 December 2020 - NetScientific plc (AIM: NSCI), the life sciences, technology, investment and commercialisation company, announces that its portfolio company PDS Biotechnology Corporation ("PDS") (Nasdaq: PDSB) today announced the publication of research by a leading vaccine research team at the Icahn School of Medicine at Mount Sinai, showing a powerful antibody induction by Versamune(R) against SARS-CoV-2 at low antigen doses, suggesting potential for an effective antigen dose sparing COVID-19 vaccine. These data are based on preclinical studies combining PDS Biotech's Versamune(R) technology with an inactivated Newcastle disease virus (NDV)/SARS-CoV-2 vaccine (NDV vaccine) developed at Mount Sinai. The peer-reviewed scientific publication "A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine" by Sun et al. was published December 17th, 2020 in Vaccines (2020, volume 8, issue 4, page 771) and provides strong rationale for clinical development of a Versamune(R)-based COVID-19 vaccine to maximize the full breadth of immune responses induced against SARS-CoV-2.

Dr. Frank Bedu-Addo, PDS Biotech's Chief Executive Officer, commented "The results of this independent preclinical study highlight the versatility and breadth of immune responses induced by Versamune(R). The power of Versamune(R) to confer rapid and long-term protection against infectious agents lies in its ability to quickly induce effective neutralizing antibody responses in addition to strong CD8+ and CD4+ T-cell responses."

"The first wave of COVID-19 vaccines focused on antibody generation. However, there is a growing body of literature that establishes the importance of T-cells in providing more durable protection against COVID-19," commented Dr. Lauren V. Wood, Chief Medical Officer of PDS Biotech, "The preclinical data that has been generated with our COVID-19 vaccine candidate, PDS0203, establishes the rapid induction of both protective neutralizing antibodies and attacking T-cells against the virus. Our encouragement of independent, expert validation of Versamune(R)'s ability to induce powerful and effective immune responses underscores our commitment to developing superior cancer therapies and vaccines."

NetScientific holds approximately 5.75% of PDS' undiluted share capital.

The full details of the announcement are set out below and can be found here:

# # #

PDS Biotech Announces Mount Sinai Publication of Studies Showing Superior Induction of Antibodies by Versamune â -based COVID-19 Vaccine

Versamune â T-cell activating platform demonstrates breadth of anti-SARS-CoV-2 immune responses in a COVID-19 vaccine

Florham Park, NJ, December 21, 2020 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune(R) T-cell activating technology, today announced the publication of data generated by a leading vaccine research team at the Icahn School of Medicine at Mount Sinai. The research demonstrated powerful antibody induction by Versamune(R) against SARS-CoV-2 at low antigen doses suggesting potential for an effective antigen dose sparing COVID-19 vaccine. These data are based on preclinical studies combining PDS Biotech's Versamune(R) technology with an inactivated Newcastle disease virus (NDV)/SARS-CoV-2 vaccine (NDV vaccine) developed at Mount Sinai. The peer-reviewed scientific publication "A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine" by Sun et al. was published December 17 th , 2020 in Vaccines ( 2020, volume 8, issue 4, page 771) and provides strong rationale for clinical development of a Versamune(R)-based COVID-19 vaccine to maximize the full breadth of immune responses induced against SARS-CoV-2.

The preclinical study compared various treatment regimens in their ability to induce antibodies against SARS-CoV-2:

-- the NDV vaccine alone at doses of 5<MU>g, 10<MU>g and 20<MU>g,

-- the NDV vaccine in combination with Versamune(R) at 0.2<MU>g, 1<MU>g and 5<MU>g,

-- and the NDV vaccine in combination with Addavax, an adjuvant well-known for its ability to induce powerful antibody responses, at 0.2<MU>g, 1<MU>g and 5<MU>g.

As seen in Figure 3B of the publication, shown below, the NDV vaccine with R-DOTAP, the active ingredient in Versamune , yielded the strongest antibody responses. Figure 3C, also shown below, highlighted Versamune 's ability to induce the highest levels of neutralizing antibodies even at the lowest studied antigen dose of 0.2<MU>g. Challenge studies also demonstrated that the Versamune -containing vaccine conferred protection against SARS-CoV-2 infection.

http://www.rns-pdf.londonstockexchange.com/rns/4155J_1-2020-12-21.pdf

PDS Biotech is jointly developing PDS0203 with the Brazilian company Farmacore. PDS0203 is a second-generation Versamune -based COVID-19 vaccine: a simple subunit vaccine that utilizes a recombinant protein derived from the Spike protein of SARS-CoV-2, as opposed to an inactivated virus-based vaccine. Preclinical studies of PDS0203 have confirmed the induction of strong neutralizing antibodies, virus-specific polyfunctional CD8+ (killer) and CD4+ (helper) T-cells, and long-term memory T-cell responses.

Dr. Frank Bedu-Addo, PDS Biotech's Chief Executive Officer, commented "The results of this independent preclinical study highlight the versatility and breadth of immune responses induced by Versamune(R). The power of Versamune(R) to confer rapid and long-term protection against infectious agents lies in its ability to quickly induce effective neutralizing antibody responses in addition to strong CD8+ and CD4+ T-cell responses."

"The first wave of COVID-19 vaccines focused on antibody generation. However, there is a growing body of literature that establishes the importance of T-cells in providing more durable protection against COVID-19," commented Dr. Lauren V. Wood, Chief Medical Officer of PDS Biotech, "The preclinical data that has been generated with our COVID-19 vaccine candidate, PDS0203, establishes the rapid induction of both protective neutralizing antibodies and attacking T-cells against the virus. Our encouragement of independent, expert validation of Versamune(R)'s ability to induce powerful and effective immune responses underscores our commitment to developing superior cancer therapies and vaccines."

The studies detailed in Vaccine were conducted under a drug testing agreement between PDS Biotech and Icahn School of Medicine at Mount Sinai.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune(R) T-cell activating technology platform. The company's lead investigational cancer immunotherapy product PDS0101 is currently in Phase 2 clinical studies in multiple indications. Versamune(R) effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has developed multiple therapies, based on combinations of Versamune(R) and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

AboutPDS0203

PDS0203 is an investigational vaccine designed for the prevention of COVID-19 being jointly developed by PDS Biotech and Farmacore. PDS0203 combines the utility of PDS Biotech's Versamune(R) platform with a recombinant native Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) protein recognizable by our immune system (antigen). The Versamune(R) platform, due to its unique ability to induce both antibody and T-cell responses is being utilized to develop a next generation vaccine that may more effectively prevent COVID-19.

# # #

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Following the publication of this announcement, this inside information is now considered to be in the public domain.

For more information, please contact:

NetScientific

Ilian Iliev, CEO Tel: +44 (0)20 3514 1800

WH Ireland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Darshan Patel Tel: +44 (0)20 7220 1666

About NetScientific

NetScientific is a life sciences, technology, investment and commercialisation Group, leveraging trans-Atlantic relationships and global opportunities to deliver shareholder value.

   For more information, please visit the website at    www.NetScientific.net 

, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RESZFLFLBLLEFBE

(END) Dow Jones Newswires

December 21, 2020 09:59 ET (14:59 GMT)